{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:35:07Z","timestamp":1794580507210,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eprac.2023.11.007","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T02:15:28Z","timestamp":1701051328000},"page":"160-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-8738","authenticated-orcid":false,"given":"Huzaifa Ul Haq","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurjeel Uddin","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahabia","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamas","family":"Ghazanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna Shakil","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Hannan","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2023.11.007_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib2","first-page":"504","article-title":"Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2023.11.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2023.11.007_bib4","series-title":"Endotext","article-title":"Lifestyle changes: effect of diet, exercise, functional food, and obesity treatment on lipids and lipoproteins","author":"Enkhmaa","year":"2000"},{"issue":"17","key":"10.1016\/j.eprac.2023.11.007_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.007_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MED.0000000000000140","article-title":"Medications for weight loss","volume":"22","author":"Mordes","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.eprac.2023.11.007_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.007_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tem.2013.01.004","article-title":"Is there a place for incretin therapies in obesity and prediabetes?","volume":"24","author":"Holst","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.eprac.2023.11.007_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.007_bib10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.007_bib11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/oby.21107","article-title":"GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond","volume":"23","author":"Ryan","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.007_bib12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial","volume":"30","author":"Maselli","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.007_bib13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/oby.23525","article-title":"Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you","volume":"30","author":"Jalleh","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"9 Pt B","key":"10.1016\/j.eprac.2023.11.007_bib14","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.bbadis.2018.05.012","article-title":"GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms","volume":"1864","author":"Rizzo","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"7","key":"10.1016\/j.eprac.2023.11.007_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","article-title":"Obesity and the risk of cardiometabolic diseases","volume":"20","author":"Valenzuela","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2023.11.007_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.eprac.2023.11.007_bib18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2023.11.007_bib19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278685","article-title":"Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis","volume":"18","author":"Yeh","year":"2023","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.007_bib21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41415-022-4359-7","article-title":"PRISMA 2020 updated guideline","volume":"232","author":"Dickson","year":"2022","journal-title":"Br Dent J"},{"key":"10.1016\/j.eprac.2023.11.007_bib22","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 3: systematic reviews of effectiveness","author":"Tufanaru","year":"2020"},{"issue":"7414","key":"10.1016\/j.eprac.2023.11.007_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.007_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"issue":"10148","key":"10.1016\/j.eprac.2023.11.007_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.eprac.2023.11.007_bib26","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2023.11.007_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.007_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.007_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.007_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9701","key":"10.1016\/j.eprac.2023.11.007_bib31","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.007_bib33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.007_bib34","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"10.1016\/j.eprac.2023.11.007_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/dc11-0931","article-title":"Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes","volume":"35","author":"Dushay","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.007_bib37","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2023.11.007_bib38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.007_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14940","article-title":"Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: a value for money analysis","volume":"25","author":"Azuri","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.007_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2023.11.007_bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.eprac.2023.11.007_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MBP.0000000000000537","article-title":"The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis","volume":"26","author":"Patoulias","year":"2021","journal-title":"Blood Press Monit"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.eprac.2023.11.007_bib48","article-title":"Abstract 15922: effect of Glp-1 receptor agonists on systolic blood pressure in patients with overweight or obesity: a network meta-analysis","volume":"146","author":"Usman","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.eprac.2023.11.007_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-019-0937-7","article-title":"Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures","volume":"18","author":"Lundgren","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.eprac.2023.11.007_bib50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"9861","key":"10.1016\/j.eprac.2023.11.007_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2023.11.007_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.11.007_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2023.11.007_bib54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"issue":"11","key":"10.1016\/j.eprac.2023.11.007_bib55","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/nu14112217","article-title":"The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials","volume":"14","author":"Alabduljabbar","year":"2022","journal-title":"Nutrients"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23007589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:16:14Z","timestamp":1761516974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23007589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1530891X23007589"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}